UCB has announced a definitive agreement to acquire Neurona Therapeutics in a deal aimed at strengthening its epilepsy portfolio and expanding into regenerative medicine. The acquisition includes Neurona’s lead investigational therapy, NRTX-1001, which is being developed to treat severe forms of epilepsy.
The move represents a strategic shift for UCB as it looks beyond traditional symptom management toward potentially disease-modifying therapies. By integrating Neurona’s regenerative cell therapy platform, UCB aims to address significant unmet needs in neurological disorders, particularly drug-resistant epilepsy.
NRTX-1001 is a novel, single-dose neural cell therapy designed to restore balance in overactive brain circuits. It works by delivering cells that produce gamma-aminobutyric acid (GABA), a key inhibitory neurotransmitter, directly into the brain. This approach is intended to repair dysfunctional neural networks and reduce seizure activity in patients with mesial temporal lobe epilepsy (mTLE), one of the most common and treatment-resistant forms of the disease.
Currently in Phase I/II clinical trials, NRTX-1001 is being evaluated for safety, tolerability, and its ability to reduce seizure frequency in patients with drug-resistant unilateral and bilateral mTLE, with or without mesial temporal sclerosis. Early data have shown promise, leading to regulatory recognition from both the U.S. Food and Drug Administration and the European Medicines Agency. The therapy has received Regenerative Medicine Advanced Therapy (RMAT) designation in the U.S. and PRIME (Priority Medicines) designation in Europe, highlighting its potential to address serious unmet medical needs.
UCB’s CEO, Jean-Christophe Tellier, emphasized that the acquisition aligns with the company’s long-standing leadership in epilepsy, a field it has helped shape for over three decades. He noted that incorporating NRTX-1001 into UCB’s pipeline could mark a significant advancement, offering the possibility of long-term or even durable seizure control following a single treatment.
Under the terms of the agreement, UCB will pay $650 million upfront, with up to $500 million in additional milestone payments tied to future development and commercialization achievements. The transaction is expected to close by the end of the second quarter of 2026, pending regulatory approvals and customary closing conditions.
Following the announcement, UCB confirmed that its 2026 financial outlook remains unchanged. The company continues to expect revenue growth in the high single-digit to low double-digit percentage range, along with strong gains in adjusted EBITDA.
The deal also reflects growing industry interest in regenerative medicine as a transformative approach to treating neurological disorders. By combining its global reach with Neurona’s innovative platform, UCB aims to accelerate the development of next-generation therapies that could fundamentally change how epilepsy is treated worldwide.